UNITED STATES
                                 SECURITIES AND EXCHANGE COMMISSION
                                              WASHINGTON, D.C. 20549


     DIVISION OF
CORPORATION FINANCE


                                                                October 2, 2019

  Via E-Mail
  Tobias L. Knapp, Esq.
  O'Melveny & Myers LLP
  Times Square Tower
  Seven Times Square
  New York, NY 10036

          Re:     Progenics Pharmaceuticals, Inc.
                  PREC14A filed on September 25, 2019
                  File No. 000-23143

  Dear Mr. Knapp:

        We have reviewed your filing and have the following comments. In some
of our comments,
  we may ask you to provide us with information so we may better understand
your disclosure.

         Please respond to this letter by amending your filing, by providing
the requested
  information, or by advising us when you will provide the requested response.
If you do not
  believe our comments apply to your facts and circumstances or do not believe
an amendment is
  appropriate, please tell us why in your response.

         After reviewing any amendment to your filing and the information you
provide in
  response to these comments, we may have additional comments.

  Preliminary Proxy Statement
  Cover page

  1.      We note your disclosure Velan's candidates would control the board
"...and, although
          they would be subject to their fiduciary duties under Delaware law,
they would be in a
          position to advance Velan's specific interests, which may not be
aligned with the interests
          of all of our shareholders." Please revise your disclosure to clarify
that Velan's
          candidates are independent of Velan. Also, clarify why you believe
that Velan's "specific
          interests" may not be aligned with the interests of other
shareholders.

  2.      Note that you must avoid issuing statements that directly or
indirectly impugn the
          character, integrity or personal reputation or make charges of
illegal, improper or
          immoral conduct without factual foundation. Provide us
supplementally, or disclose, the
          factual foundation for your disclosure referencing "past activities
of Velan's group
          members in other pharmaceutical business involved in questionable
business practices,
          such as reported price gouging and illegal kickbacks." In this
regard, note that the factual
          foundation for such assertion must be reasonable. Refer to Rule
14a-9.
 Tobias L. Knapp, Esq.
O'Melveny & Myers LLP
October 2, 2019
Page 2

3.     Each statement or assertion of opinion or belief must be clearly
characterized as such,
       and a reasonable factual basis must exist for each such opinion or
belief. Support for
       opinions or beliefs should be self-evident, disclosed in the proxy
statement or provided to
       the staff on a supplemental basis. Provide support for your statement
that the company is
       a "leading company un using artificial intelligence in treating prostate
cancer."

Reasons to Reject the Velan Consent Proposals, page 3

4.     Please revise the section relating to Proposal 4 to clarify that the
Velan proposal would
       not, as written, permanently restrict the ability of the board or
shareholders to adjust the
       size of the board. In addition, provide support for your belief that
proposal 4 "...reflects
       Velan's attempt at locking in its influence over the Board by
restricting new
       membership."

Background of the Velan Consent Solicitation, page 6

5.     We note that your entry for the events of July 26, 2019 differs from the
description
       provided by Velan in its proxy statement. Please revise your disclosure
to provide
       additional background or advise.

        We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff

       Please direct any questions to me at (202) 551-3619.

                                                             Sincerely,

                                                             /s/ Daniel F.
Duchovny
                                                             Daniel F. Duchovny
                                                             Special Counsel
                                                             Office of Mergers
and Acquisitions